A preclinical study has found multiple myeloma is highly sensitive to a newly developed experimental therapy, according to research published today by Peter Mac scientists.
A preclinical study has found multiple myeloma is highly sensitive to a newly developed experimental therapy, according to research published today by Peter Mac scientists.
